|
humans |
39 |
|
male |
24 |
|
aged |
23 |
|
female |
23 |
|
middle aged |
22 |
|
adult |
19 |
|
gastric cancer |
17 |
|
medical sciences |
17 |
|
helicobacter pylori |
14 |
|
aged, 80 and over |
13 |
|
stomach neoplasms - genetics - pathology |
12 |
|
prognosis |
11 |
|
treatment outcome |
11 |
|
gene expression regulation, neoplastic |
10 |
|
mutation |
10 |
|
prevalence |
10 |
|
proto-oncogene proteins - genetics |
10 |
|
transcription factors - genetics |
10 |
|
antigens, cd44 - genetics - metabolism |
9 |
|
gastric carcinoma |
9 |
|
immunoglobulin heavy chains - genetics |
9 |
|
immunohistochemistry |
9 |
|
lymphoma, follicular - genetics - pathology |
9 |
|
lymphoma, large b-cell, diffuse - genetics - pathology |
9 |
|
stomach neoplasms - genetics |
9 |
|
base sequence |
8 |
|
cadherins - blood |
8 |
|
dna mutational analysis |
8 |
|
drug therapy, combination |
8 |
|
enzyme inhibitors - therapeutic use |
8 |
|
gist |
8 |
|
promoter regions, genetic |
8 |
|
tumor markers, biological - blood |
8 |
|
adenocarcinoma - blood - diagnosis |
7 |
|
cell proliferation - drug effects |
7 |
|
diagnosis |
7 |
|
dna-binding proteins - genetics |
7 |
|
e-cadherin |
7 |
|
gastric adenocarcinoma |
7 |
|
hong kong |
7 |
|
lymphoma - epidemiology - genetics |
7 |
|
nicotine |
7 |
|
predictive value of tests |
7 |
|
prospective studies |
7 |
|
proto-oncogene proteins c-bcl-6 |
7 |
|
stomach neoplasms - blood - diagnosis |
7 |
|
stomach neoplasms - epidemiology - genetics |
7 |
|
translocation, genetic |
7 |
|
tumor marker |
7 |
|
adolescent |
6 |
|
anti-bacterial agents - pharmacology - therapeutic use |
6 |
|
anti-bacterial agents - therapeutic use |
6 |
|
anti-ulcer agents - therapeutic use |
6 |
|
breath tests |
6 |
|
clarithromycin - therapeutic use |
6 |
|
colon cancer |
6 |
|
gastroenterology |
6 |
|
helicobacter infections - complications |
6 |
|
helicobacter infections - drug therapy |
6 |
|
microsatellite repeats - genetics |
6 |
|
omeprazole - pharmacology - therapeutic use |
6 |
|
omeprazole - therapeutic use |
6 |
|
palliative care |
6 |
|
postoperative complications |
6 |
|
retrospective studies |
6 |
|
survival rate |
6 |
|
academic medical centers |
5 |
|
adc |
5 |
|
amoxicillin - pharmacology - therapeutic use |
5 |
|
anti-inflammatory agents, non-steroidal - adverse effects |
5 |
|
carcinoembryonic antigen |
5 |
|
cigarette smoke |
5 |
|
decorin |
5 |
|
diffusion magnetic resonance imaging |
5 |
|
dna methylation |
5 |
|
dna-binding proteins - biosynthesis - genetics |
5 |
|
double-blind method |
5 |
|
drug administration schedule |
5 |
|
emt |
5 |
|
fibrosis |
5 |
|
gene expression profiling |
5 |
|
h(+)-k(+)-exchanging atpase - antagonists & inhibitors |
5 |
|
helicobacter infections - drug therapy - metabolism |
5 |
|
hong kong - epidemiology |
5 |
|
hospital mortality |
5 |
|
immunoglobulins - chemistry |
5 |
|
inflammation |
5 |
|
li-cadherin |
5 |
|
lymphoma - genetics |
5 |
|
molecular sequence data |
5 |
|
morbidity |
5 |
|
neoplasm staging |
5 |
|
nicotine - pharmacology |
5 |
|
ofloxacin - pharmacology - therapeutic use |
5 |
|
oligonucleotide array sequence analysis |
5 |
|
pancreaticoduodenectomy - mortality - standards |
5 |
|
peptic ulcer - chemically induced - microbiology - prevention & control |
5 |
|
peritoneal dialysis |
5 |
|
peritonitis |
5 |
|
pet/ct |
5 |
|
protein transport |
5 |
|
recurrence |
5 |
|
recurrence - prevention & control |
5 |
|
referral and consultation |
5 |
|
risk factors |
5 |
|
rna, messenger - genetics |
5 |
|
rt-pcr |
5 |
|
sequence homology, nucleic acid |
5 |
|
stomach neoplasms - diagnosis - genetics - mortality |
5 |
|
stress |
5 |
|
suv |
5 |
|
tumour marker |
5 |
|
1-phosphatidylinositol 3-kinase - genetics |
4 |
|
2-pyridinylmethylsulfinylbenzimidazoles |
4 |
|
acp |
4 |
|
adenocarcinoma - diagnosis - genetics - mortality |
4 |
|
adenocarcinoma - etiology - genetics - metabolism |
4 |
|
adenocarcinoma - genetics |
4 |
|
adenocarcinoma - genetics - metabolism |
4 |
|
adenocarcinoma - metabolism - pathology |
4 |
|
adenocarcinoma - metabolism - physiopathology |
4 |
|
adrenaline |
4 |
|
adrenergic beta-antagonists - pharmacology |
4 |
|
airway obstruction - therapy |
4 |
|
algorithms |
4 |
|
amoxicillin - therapeutic use |
4 |
|
anti-infective agents - pharmacology - therapeutic use |
4 |
|
anti-ulcer agents - pharmacology - therapeutic use |
4 |
|
antibodies, bispecific |
4 |
|
antineoplastic agents - therapeutic use |
4 |
|
atenolol - pharmacology |
4 |
|
azacitidine - analogs & derivatives - therapeutic use |
4 |
|
bax |
4 |
|
bcl-2-associated x protein |
4 |
|
biliary tract neoplasms - complications - mortality |
4 |
|
biomarker |
4 |
|
biopsy - instrumentation - methods |
4 |
|
bismuth |
4 |
|
blotting, western |
4 |
|
breast neoplasms - blood - diagnosis - genetics - pathology |
4 |
|
butadienes - pharmacology |
4 |
|
cadherins |
4 |
|
cadherins - genetics - metabolism |
4 |
|
capd |
4 |
|
carbon isotopes - diagnostic use |
4 |
|
carcinoma - genetics - pathology - virology |
4 |
|
carcinoma, hepatocellular - mortality - surgery |
4 |
|
carcinoma, squamous cell - mortality - therapy |
4 |
|
cardia |
4 |
|
cardiopulmonary resuscitation |
4 |
|
cardiopulmonary resuscitation - adverse effects |
4 |
|
carrier proteins - genetics - metabolism |
4 |
|
ccl |
4 |
|
cdx2 |
4 |
|
cell line |
4 |
|
cell line, tumor |
4 |
|
cell survival - drug effects |
4 |
|
cell transformation, neoplastic - genetics |
4 |
|
cells, cultured |
4 |
|
chemokine (c-c motif) ligand |
4 |
|
chemokines, cc - genetics - immunology |
4 |
|
choledochostomy |
4 |
|
cholestasis - etiology - surgery |
4 |
|
cholestasis - mortality - surgery - therapy |
4 |
|
ci |
4 |
|
circulating microrna |
4 |
|
clarithromycin |
4 |
|
clarithromycin - pharmacology - therapeutic use |
4 |
|
collagen type i - genetics |
4 |
|
combined modality therapy |
4 |
|
complication |
4 |
|
confidence interval |
4 |
|
connective tissue growth factor - genetics - metabolism |
4 |
|
cox-2 |
4 |
|
cpg islands - genetics |
4 |
|
cpr |
4 |
|
ctgf/ccn2 |
4 |
|
culture media, conditioned |
4 |
|
cyclooxygenase 2 - biosynthesis |
4 |
|
cytokines - genetics - metabolism |
4 |
|
diagnostic marker |
4 |
|
dialysis solutions - toxicity |
4 |
|
disease progression |
4 |
|
dna methylation - genetics |
4 |
|
dna microarray |
4 |
|
dna modification methylases - antagonists & inhibitors |
4 |
|
dna primers |
4 |
|
dna, neoplasm - genetics |
4 |
|
dna-binding proteins - metabolism |
4 |
|
dose-response relationship, drug |
4 |
|
down-regulation |
4 |
|
down-regulation - genetics |
4 |
|
drainage |
4 |
|
drug resistance |
4 |
|
drug synergism |
4 |
|
drug therapy, combination - methods |
4 |
|
dyspepsia - pathology |
4 |
|
empirical first-line eradication |
4 |
|
endoscopy, digestive system - instrumentation |
4 |
|
endothelial cells - drug effects - metabolism - pathology |
4 |
|
enzyme induction - drug effects |
4 |
|
enzyme-linked immunosorbent assay |
4 |
|
ep4 |
4 |
|
epithelial cells - drug effects - metabolism - pathology |
4 |
|
epithelial cells - physiology |
4 |
|
epstein-barr virus |
4 |
|
equipment reuse |
4 |
|
esophageal neoplasms - mortality - therapy |
4 |
|
esophageal neoplasms - psychology - surgery |
4 |
|
esophagectomy |
4 |
|
exome |
4 |
|
extracellular signal-regulated map kinases - metabolism |
4 |
|
fibroblasts - drug effects - metabolism - pathology |
4 |
|
first aid - adverse effects |
4 |
|
follow-up studies |
4 |
|
gastric mucosa - physiology |
4 |
|
gastric rupture |
4 |
|
gastritis |
4 |
|
gene amplification |
4 |
|
gene expression - drug effects |
4 |
|
gene expression regulation, neoplastic - immunology |
4 |
|
gene silencing |
4 |
|
genes, tumor suppressor - genetics |
4 |
|
hazard ratio |
4 |
|
heimlich maneuver |
4 |
|
helicobacter |
4 |
|
helicobacter infections - drug therapy - pathology |
4 |
|
helicobacter pylori - drug effects |
4 |
|
helix-loop-helix motifs |
4 |
|
hepatectomy |
4 |
|
herpesviridae infections - complications |
4 |
|
herpesvirus 4, human - pathogenicity |
4 |
|
histone deacetylase inhibitors |
4 |
|
hmlh1 |
4 |
|
homeodomain proteins - genetics - metabolism |
4 |
|
hong kong chinese |
4 |
|
hr |
4 |
|
hydroxamic acids - therapeutic use |
4 |
|
id4 |
4 |
|
ihc |
4 |
|
immunoenzyme techniques |
4 |
|
inhibitor of differentiation proteins |
4 |
|
interleukin-6 - genetics |
4 |
|
intestinal metaplasia |
4 |
|
jak-stat |
4 |
|
leptin |
4 |
|
leptin - physiology |
4 |
|
leptin receptor |
4 |
|
levofloxacin |
4 |
|
liver neoplasms - mortality - surgery |
4 |
|
liver neoplasms - surgery - therapy |
4 |
|
lymph node metastasis |
4 |
|
lymphatic metastasis |
4 |
|
lymphatic metastasis - genetics |
4 |
|
macrophage migration-inhibitory factor |
4 |
|
macrophage migration-inhibitory factors - blood |
4 |
|
macrophages - physiology |
4 |
|
matrix metalloproteinase |
4 |
|
matrix metalloproteinase 9 - genetics |
4 |
|
medical education |
4 |
|
membrane proteins - biosynthesis |
4 |
|
membrane transport proteins |
4 |
|
membrane transport proteins - genetics |
4 |
|
mesothelial cell |
4 |
|
metaplasia - metabolism |
4 |
|
metronidazole - pharmacology - therapeutic use |
4 |
|
metronidazole - therapeutic use |
4 |
|
microarray |
4 |
|
micrornas - physiology |
4 |
|
microsatellite instability |
4 |
|
microsatellite repeats |
4 |
|
mir-92 |
4 |
|
mitogens - pharmacology |
4 |
|
mmp |
4 |
|
mucosal immunity |
4 |
|
neoplasm proteins - genetics - metabolism |
4 |
|
neoplasm recurrence, local - blood |
4 |
|
neoplasm staging - methods |
4 |
|
nf-kappa b - physiology |
4 |
|
nf-κb |
4 |
|
nitriles - pharmacology |
4 |
|
notch1 |
4 |
|
nuclear proteins - genetics |
4 |
|
ofloxacin - therapeutic use |
4 |
|
online synchronous education |
4 |
|
online teaching |
4 |
|
pancreatic neoplasms - complications |
4 |
|
parenteral nutrition |
4 |
|
peritoneal dialysis, continuous ambulatory - adverse effects |
4 |
|
peritoneum - cytology |
4 |
|
peritoneum - drug effects - metabolism - pathology |
4 |
|
phosphorylation - drug effects |
4 |
|
polymerase chain reaction |
4 |
|
postoperative complications - epidemiology - mortality |
4 |
|
precancerous conditions - metabolism |
4 |
|
preoperative care |
4 |
|
proliferation |
4 |
|
promoter methylation |
4 |
|
propanolamines - pharmacology |
4 |
|
proportional hazards models |
4 |
|
protein kinase c |
4 |
|
protein kinase c - metabolism |
4 |
|
protein kinase inhibitors - pharmacology |
4 |
|
protein transport - drug effects |
4 |
|
proto-oncogene proteins c-bcl-2 |
4 |
|
quality of life |
4 |
|
ranitidine - analogs & derivatives |
4 |
|
receptors, adrenergic, beta - drug effects - metabolism |
4 |
|
receptors, cell surface - biosynthesis |
4 |
|
receptors, leptin |
4 |
|
receptors, prostaglandin e, ep2 subtype - physiology |
4 |
|
receptors, prostaglandin e, ep4 subtype - physiology |
4 |
|
receptors, transforming growth factor beta - genetics |
4 |
|
respiratory diseases |
4 |
|
reverse transcriptase polymerase chain reaction - methods |
4 |
|
reverse-transcription polymerase chain reaction |
4 |
|
rna, messenger - genetics - metabolism |
4 |
|
signal transduction - drug effects |
4 |
|
specimen handling - instrumentation - methods - nursing |
4 |
|
ssc |
4 |
|
standard saline citrate |
4 |
|
statistics, nonparametric |
4 |
|
staurosporine - pharmacology |
4 |
|
stomach - pathology |
4 |
|
stomach neoplasms - blood - diagnosis - genetics - pathology |
4 |
|
stomach neoplasms - blood - diagnosis - mortality |
4 |
|
stomach neoplasms - blood - surgery |
4 |
|
stomach neoplasms - etiology - genetics - metabolism |
4 |
|
stomach neoplasms - genetics - metabolism |
4 |
|
stomach neoplasms - genetics - pathology - virology |
4 |
|
stomach neoplasms - metabolism - pathology |
4 |
|
stomach neoplasms - metabolism - physiopathology |
4 |
|
stomach neoplasms - pathology |
4 |
|
stomach neoplasms - psychology - surgery |
4 |
|
stomach rupture - etiology |
4 |
|
survival analysis |
4 |
|
t-lymphocytes - immunology |
4 |
|
tartrate-resistant acid phosphatase |
4 |
|
tgf-β |
4 |
|
transcription factor ap-1 - biosynthesis |
4 |
|
transcription factors - metabolism |
4 |
|
transforming growth factor beta - biosynthesis |
4 |
|
transforming growth factor beta - genetics - metabolism |
4 |
|
tumor markers, biological - analysis |
4 |
|
tumor markers, biological - genetics |
4 |
|
tumor markers, biological - genetics - metabolism |
4 |
|
tumor virus infections - complications |
4 |
|
tβrii |
4 |
|
undergraduate education |
4 |
|
up-regulation |
4 |
|
urea - analysis |
4 |
|
vascular endothelial growth factor a - genetics - metabolism |
4 |
|
vegf |
4 |
|
β-adrenergic receptor |
4 |
|
5-lox |
3 |
|
adenocarcinoma - complications - microbiology |
3 |
|
administration, oral |
3 |
|
analgesics, opioid - pharmacology |
3 |
|
anastomosis, surgical |
3 |
|
animals |
3 |
|
antacids - administration & dosage - therapeutic use |
3 |
|
anti-bacterial agents - administration & dosage - therapeutic use |
3 |
|
anti-infective agents - administration & dosage - adverse effects - pharmacology |
3 |
|
anti-inflammatory agents, non-steroidal - administration & dosage - adverse effects - therapeutic use |
3 |
|
anti-obesity agents - adverse effects - pharmacokinetics - pharmacology |
3 |
|
anti-ulcer agents - administration & dosage |
3 |
|
anti-ulcer agents - administration & dosage - therapeutic use |
3 |
|
antibodies, bacterial - blood |
3 |
|
apoptosis - drug effects |
3 |
|
arachidonate 5-lipoxygenase - metabolism |
3 |
|
asian continental ancestry group - ethnology |
3 |
|
aspirin - administration & dosage |
3 |
|
bacterial artificial chromosome |
3 |
|
bile - chemistry |
3 |
|
bile acids and salts - chemistry |
3 |
|
biliary obstruction |
3 |
|
biopsy |
3 |
|
blood vessels - drug effects |
3 |
|
c-myc |
3 |
|
cancer cell |
3 |
|
carcinogens - toxicity |
3 |
|
carcinoma |
3 |
|
carcinoma - genetics |
3 |
|
carcinoma - metabolism - virology |
3 |
|
carcinoma, hepatocellular |
3 |
|
carcinoma, hepatocellular - surgery |
3 |
|
carcinoma, squamous cell - genetics |
3 |
|
carcinoma, squamous cell - mortality - surgery |
3 |
|
celecoxib |
3 |
|
cell division - drug effects |
3 |
|
cell proliferation |
3 |
|
chi-square distribution |
3 |
|
cholangiocarcinoma |
3 |
|
cholesterol - metabolism |
3 |
|
chromosome aberrations |
3 |
|
chromosome deletion |
3 |
|
cirrhosis |
3 |
|
clarithromycin - administration & dosage - therapeutic use |
3 |
|
clinical trials as topic |
3 |
|
cohort studies |
3 |
|
cold temperature |
3 |
|
comparative genomic hybridization |
3 |
|
complementary dna |
3 |
|
cyclin d1 - genetics |
3 |
|
cyclooxygenase 2 inhibitors - adverse effects - therapeutic use |
3 |
|
cyclooxygenase-2 |
3 |
|
digestive system surgical procedures - methods |
3 |
|
distance learning |
3 |
|
dna, satellite - genetics |
3 |
|
drainage - methods |
3 |
|
duodenal ulcer - drug therapy - microbiology - pathology |
3 |
|
dyspepsia - chemically induced |
3 |
|
endoscopes - adverse effects |
3 |
|
endoscopy, digestive system - adverse effects |
3 |
|
energy intake |
3 |
|
enzyme inhibitors - adverse effects - pharmacokinetics - pharmacology |
3 |
|
enzyme-linked immunosorbent assay - methods - standards |
3 |
|
epithelial cells - cytology |
3 |
|
eradication |
3 |
|
esophageal neoplasms - genetics |
3 |
|
esophageal neoplasms - mortality - pathology - surgery |
3 |
|
esophageal neoplasms - mortality - surgery |
3 |
|
esophageal neoplasms - radiography - surgery |
3 |
|
esophageal neoplasms - surgery |
3 |
|
esophagectomy - adverse effects |
3 |
|
esophagectomy - methods |
3 |
|
european continental ancestry group - ethnology |
3 |
|
gallbladder - drug effects - physiology |
3 |
|
gastric mucosa - blood supply - drug effects - pathology |
3 |
|
gastric ulcer |
3 |
|
genes, ras |
3 |
|
head and neck neoplasms - metabolism - virology |
3 |
|
helicobacter infections - complications - microbiology |
3 |
|
helicobacter infections - diagnosis - ethnology |
3 |
|
helicobacter pylori - immunology |
3 |
|
helicobacter pylori - isolation and purification |
3 |
|
hepatectomy - methods |
3 |
|
hepatic resection |
3 |
|
hepatitis, chronic - pathology - surgery |
3 |
|
hepatolithiasis |
3 |
|
herpesvirus 4, human - isolation & purification |
3 |
|
hyperalimentation |
3 |
|
iatrogenic disease |
3 |
|
immunoglobulin g - blood |
3 |
|
in situ hybridization |
3 |
|
in situ hybridization, fluorescence - methods |
3 |
|
incidence |
3 |
|
interleukin-1beta - genetics |
3 |
|
intraoperative complications - etiology - prevention & control |
3 |
|
karyotyping |
3 |
|
lactones - adverse effects - pharmacokinetics - pharmacology |
3 |
|
lansoprazole |
3 |
|
lipase - antagonists & inhibitors |
3 |
|
lipids - analysis |
3 |
|
liver - pathology |
3 |
|
liver cirrhosis - pathology - surgery |
3 |
|
liver neoplasms - pathology - surgery |
3 |
|
liver neoplasms - surgery |
3 |
|
liver resection |
3 |
|
lung diseases - etiology |
3 |
|
lymphoma, b-cell, marginal zone - complications - microbiology |
3 |
|
mesoderm - cytology |
3 |
|
metronidazole - administration & dosage - therapeutic use |
3 |
|
midline incision |
3 |
|
mir-940 |
3 |
|
morphine |
3 |
|
morphine - pharmacology |
3 |
|
mortality |
3 |
|
mucus |
3 |
|
myeloperoxidase |
3 |
|
naloxone - pharmacology |
3 |
|
naproxen - administration & dosage - adverse effects - therapeutic use |
3 |
|
neoplasm proteins - genetics |
3 |
|
new south wales - epidemiology |
3 |
|
nitrosamines - toxicity |
3 |
|
nsaids |
3 |
|
nutritional support |
3 |
|
obesity - drug therapy - metabolism |
3 |
|
oesophagus |
3 |
|
omeprazole - administration & dosage |
3 |
|
omeprazole - administration & dosage - adverse effects - analogs & derivatives - pharmacology |
3 |
|
omeprazole - administration & dosage - analogs & derivatives - therapeutic use |
3 |
|
oncogene proteins - genetics |
3 |
|
online education |
3 |
|
organometallic compounds - therapeutic use |
3 |
|
ornithine decarboxylase |
3 |
|
p53 |
3 |
|
pbl |
3 |
|
peptic ulcer - chemically induced - epidemiology - prevention & control |
3 |
|
peptic ulcer hemorrhage - chemically induced |
3 |
|
peptic ulcer hemorrhage - etiology - prevention & control |
3 |
|
plasma |
3 |
|
platelet aggregation inhibitors - administration & dosage |
3 |
|
pleural drainage |
3 |
|
pneumoperitoneum - etiology - radiography |
3 |
|
postoperative care |
3 |
|
postoperative complications - epidemiology - prevention & control |
3 |
|
problem-based learning |
3 |
|
proto-oncogene proteins b-raf |
3 |
|
proton pumps - antagonists & inhibitors |
3 |
|
pylorus - surgery |
3 |
|
pyrazoles - adverse effects - therapeutic use |
3 |
|
radical gastrectomy surgery |
3 |
|
rats |
3 |
|
rats, sprague-dawley |
3 |
|
receptors, prostaglandin e, ep2 subtype - metabolism |
3 |
|
receptors, prostaglandin e, ep4 subtype - metabolism |
3 |
|
reconstructive surgical procedures |
3 |
|
sensitivity and specificity |
3 |
|
snail |
3 |
|
sphincterotomy, endoscopic - adverse effects - mortality - statistics & numerical data |
3 |
|
stomach - drug effects - pathology |
3 |
|
stomach - surgery |
3 |
|
stomach neoplasms - chemically induced - metabolism |
3 |
|
stomach neoplasms - complications - microbiology |
3 |
|
stomach neoplasms - enzymology - pathology |
3 |
|
stomach neoplasms - etiology |
3 |
|
stomach neoplasms - genetics - metabolism - pathology |
3 |
|
stomach neoplasms - metabolism - virology |
3 |
|
stomach neoplasms - surgery |
3 |
|
stomach ulcer - complications |
3 |
|
stomach ulcer - etiology - prevention & control |
3 |
|
stress, physiological - complications |
3 |
|
stromal tumour |
3 |
|
stump |
3 |
|
subcostal rooftop incision |
3 |
|
sulfonamides - adverse effects - therapeutic use |
3 |
|
surgical skills |
3 |
|
suture techniques |
3 |
|
syndrome |
3 |
|
telecommunication |
3 |
|
ticlopidine - administration & dosage - analogs & derivatives |
3 |
|
time factors |
3 |
|
tumor suppressor protein p53 - metabolism |
3 |
|
ulcers |
3 |
|
undergraduate |
3 |
|
weight loss |
3 |
|
wound healing - drug effects |
3 |
|
abdominal compartment syndrome |
2 |
|
abdominal pain - diagnosis - etiology |
2 |
|
acute disease |
2 |
|
adenocarcinoma - etiology - pathology |
2 |
|
adenocarcinoma - genetics - metabolism - pathology |
2 |
|
adrenergic receptors |
2 |
|
amplification |
2 |
|
angiogenesis |
2 |
|
anti-infective agents - therapeutic use |
2 |
|
apoptosis regulatory proteins - genetics |
2 |
|
appendicitis - complications - diagnosis |
2 |
|
array cgh |
2 |
|
assessment |
2 |
|
autonomic nerve tumor |
2 |
|
biocompatible materials |
2 |
|
cadherins - genetics |
2 |
|
cadherins - metabolism |
2 |
|
calcium-calmodulin-dependent protein kinases - genetics |
2 |
|
carcinoma, squamous cell - complications - diagnosis - surgery |
2 |
|
child |
2 |
|
child, preschool |
2 |
|
childhood dyspepsia |
2 |
|
cholangiocellular carcinoma |
2 |
|
choristoma - microbiology |
2 |
|
chromosomes, human, pair 19 |
2 |
|
citric acid - administration & dosage |
2 |
|
clinical application |
2 |
|
cluster analysis |
2 |
|
colon and rectal obstruction |
2 |
|
colorectal neoplasms - complications - mortality - radiography - surgery |
2 |
|
colostomy - instrumentation |
2 |
|
coronavirus disease 2019 |
2 |
|
cpg island methylator phenotype |
2 |
|
crohn's disease |
2 |
|
cyclin e - genetics - metabolism |
2 |
|
cytoskeletal proteins |
2 |
|
diagnosis, differential |
2 |
|
dna modification methylases |
2 |
|
dna repair enzymes |
2 |
|
dna, neoplasm - analysis |
2 |
|
drug combinations |
2 |
|
drug resistance, bacterial |
2 |
|
duodenal diseases - complications - diagnosis - surgery |
2 |
|
duodenal obstruction - complications - diagnosis |
2 |
|
duodenal ulcer |
2 |
|
dyspepsia - etiology |
2 |
|
dyspepsia - microbiology |
2 |
|
e-learning |
2 |
|
early gastric cancer |
2 |
|
education |
2 |
|
endoscopy |
2 |
|
endoscopy, gastrointestinal |
2 |
|
epstein-barr virus infections - etiology - pathology |
2 |
|
esophagus |
2 |
|
fatal outcome |
2 |
|
gastric mucosa |
2 |
|
gastric tumor |
2 |
|
gastric ulceration |
2 |
|
gastrointestinal neoplasms - genetics - pathology |
2 |
|
gene dosage |
2 |
|
gene expression |
2 |
|
general surgery |
2 |
|
genes, p16 |
2 |
|
genes, tumor suppressor |
2 |
|
graft vs host disease - complications - pathology |
2 |
|
group ii phospholipases a2 |
2 |
|
haemorrhage |
2 |
|
helicobacter infections - diagnosis |
2 |
|
helicobacter infections - epidemiology |
2 |
|
helicobacter pylori - isolation & purification |
2 |
|
hematopoietic stem cell transplantation - adverse effects |
2 |
|
herpesvirus 4, human - genetics - metabolism |
2 |
|
human |
2 |
|
il-2r |
2 |
|
interleukin-6 |
2 |
|
interleukin-6 - blood |
2 |
|
intestinal fistula - complications - diagnosis - surgery |
2 |
|
intestinal neoplasms - genetics |
2 |
|
intestinal obstruction - etiology - mortality - radiography - surgery |
2 |
|
intra-abdominal hypertension |
2 |
|
intrahepatic cholangiocarcinoma |
2 |
|
kidney calculi - complications - diagnosis - surgery |
2 |
|
kidney neoplasms - complications - diagnosis - surgery |
2 |
|
kidney pelvis - physiopathology - radiography |
2 |
|
kit |
2 |
|
laparoscopy |
2 |
|
laparotomy - methods |
2 |
|
meckel diverticulum - microbiology |
2 |
|
meckel's diverticulum |
2 |
|
metallic stents |
2 |
|
microarrays |
2 |
|
microrna |
2 |
|
mirna |
2 |
|
multiple myeloma - therapy |
2 |
|
mutations |
2 |
|
nachrs |
2 |
|
neoplasms, second primary |
2 |
|
nnk |
2 |
|
omeprazole - analogs & derivatives - therapeutic use |
2 |
|
oncogene proteins - genetics - metabolism |
2 |
|
oncogenes |
2 |
|
organometallic compounds |
2 |
|
patient compliance |
2 |
|
pdgfra |
2 |
|
peptic ulcer |
2 |
|
peptic ulcer - chemically induced - drug therapy |
2 |
|
phospholipases a - biosynthesis - genetics |
2 |
|
phosphoproteins - genetics |
2 |
|
promoter regions, genetic - genetics |
2 |
|
prosthesis implantation - instrumentation |
2 |
|
protein kinase c - genetics |
2 |
|
protein profiling |
2 |
|
proto-oncogene proteins c-kit |
2 |
|
receptor, ephb2 - biosynthesis - genetics |
2 |
|
receptor, platelet-derived growth factor alpha - genetics |
2 |
|
reverse transcriptase polymerase chain reaction |
2 |
|
risk assessment |
2 |
|
simulation |
2 |
|
skin lesion |
2 |
|
stomach diseases - microbiology |
2 |
|
stomach neoplasms - diagnosis - mortality - pathology |
2 |
|
stomach neoplasms - etiology - pathology |
2 |
|
stromal cells - pathology |
2 |
|
stromal tumor |
2 |
|
tablets |
2 |
|
tetracycline - therapeutic use |
2 |
|
tomography, x-ray computed |
2 |
|
tumor biomarkers |
2 |
|
tumor suppressor protein p14arf - genetics |
2 |
|
tumor suppressor proteins |
2 |
|
two-dimensional gel electrophoresis |
2 |
|
ulcerative colitis |
2 |
|
ultrastructural |
2 |
|
urea - administration & dosage - analysis |
2 |
|
urea breath test |
2 |
|
urinary fistula - complications - diagnosis - surgery |
2 |
|
adenocarcinoma - surgery |
1 |
|
adenomatous polyposis coli - epidemiology - genetics - therapy |
1 |
|
adenomyoma - ultrasonography |
1 |
|
aerosol |
1 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
1 |
|
asian continental ancestry group |
1 |
|
asian patients |
1 |
|
bile duct neoplasms - complications |
1 |
|
biliary stricture |
1 |
|
c-fos |
1 |
|
c-jun |
1 |
|
capsule endoscopy |
1 |
|
cautery |
1 |
|
chinese |
1 |
|
cholestasis - etiology - therapy |
1 |
|
choristoma |
1 |
|
circulating biomarker |
1 |
|
circulating dna |
1 |
|
circulating mirna |
1 |
|
colorectal neoplasms - epidemiology - genetics - therapy |
1 |
|
cryoglobulin |
1 |
|
cyclooxygenase |
1 |
|
cytology and histology |
1 |
|
demography |
1 |
|
dna markers |
1 |
|
early detection |
1 |
|
endoscopy - methods |
1 |
|
endosonography - methods |
1 |
|
epothilones - adverse effects - therapeutic use |
1 |
|
exosomal mirna |
1 |
|
extracellular signal-regulated protein kinases |
1 |
|
fluorouracil - administration and dosage |
1 |
|
gallbladder neoplasms - complications |
1 |
|
gastrectomy |
1 |
|
gastrectomy - psychology |
1 |
|
gastrointestinal bleeding |
1 |
|
gastrointestinal diseases - psychology |
1 |
|
haematogenous metastasis |
1 |
|
hbv |
1 |
|
health status |
1 |
|
helicobacter infections |
1 |
|
her2 |
1 |
|
human epidermal growth factor receptor 2 |
1 |
|
ixabepilone |
1 |
|
language |
1 |
|
liver - surgery |
1 |
|
malignancy |
1 |
|
metastasis |
1 |
|
mirna markers |
1 |
|
multiple organ resection |
1 |
|
neoplasms |
1 |
|
obscure origin |
1 |
|
oncology medical sciences |
1 |
|
pancreas |
1 |
|
pancreatectomy |
1 |
|
pancreatic pseudocyst |
1 |
|
peptic ulcer, surgery |
1 |
|
prostheses |
1 |
|
psychometrics |
1 |
|
quality control |
1 |
|
quality of life - psychology |
1 |
|
questionnaires |
1 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
1 |
|
registries |
1 |
|
reproducibility of results |
1 |
|
respirator |
1 |
|
second-line therapy |
1 |
|
self-report |
1 |
|
splenectomy |
1 |
|
stents |
1 |
|
stomach neoplasms |
1 |
|
stomach neoplasms - complications |
1 |
|
stomach neoplasms - drug therapy - mortality |
1 |
|
stomach neoplasms - ultrasonography |
1 |
|
structural aortic abnormality |
1 |
|
surgery |
1 |
|
toxicity |
1 |
|
translations |
1 |
|
tubulin modulators - therapeutic use |
1 |
|
tumor |
1 |
